ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Status Completed

Clinical Trial Summary

This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Clinical Trial Description

OBJECTIVES:

I. Estimate the antitumor activity of ABI-007 in patients with persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix who have failed on higher-priority treatment protocols.

II. Determine the nature and degree of toxicity of ABI-007 in this cohort of patients.

III. To determine the expression of the SPARC (secreted protein, acidic and rich in cysteine) protein in the tumor tissue and plasma (exploratory study) of patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study.

Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and periodically during study for SPARC protein expression analysis by ELISA. Archived tumor tissue samples are also analyzed.

After completion of study treatment, patients are followed periodically for up to 5 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00309959
Study type	Interventional
Source	Gynecologic Oncology Group
Contact
Status	Completed
Phase	Phase 2
Start date	November 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02562729` - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer	Phase 2
Completed	`NCT00416455` - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Phase 1/Phase 2
Completed	`NCT00054444` - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer	Phase 1
Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
Active, not recruiting	`NCT02140021` - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer	N/A
Completed	`NCT00068549` - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer	Phase 1
Completed	`NCT01711515` - Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer	Phase 1
Terminated	`NCT00924066` - Ixabepilone to Treat Cervical Cancer	Phase 2
Completed	`NCT00559377` - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer	Phase 2
Active, not recruiting	`NCT05613283` - Primary Cervical Cancer Screening by Self-sampling HPV Test
Recruiting	`NCT03742869` - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
Withdrawn	`NCT03834571` - Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women	Phase 2
Completed	`NCT01266460` - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer	Phase 2
Completed	`NCT00064077` - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	Phase 3
Active, not recruiting	`NCT02257528` - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer	Phase 2
Active, not recruiting	`NCT02466971` - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers	Phase 3
Completed	`NCT02164461` - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer	Phase 1
Completed	`NCT01281852` - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer	Phase 1
Active, not recruiting	`NCT04622670` - Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer	N/A
Completed	`NCT02921269` - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer	Phase 2